Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results

Documenti analoghi

• Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
  di: Flaherty, Keith T., et al.
  Pubblicazione: (2012)
• MEK inhibitors in non-V600 BRAF mutations and fusions
  di: Johnson, Douglas B., et al.
  Pubblicazione: (2020)
• BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
  di: Ros, Javier, et al.
  Pubblicazione: (2021)
• Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF(V600)-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
  di: Johnson, Douglas B., et al.
  Pubblicazione: (2014)
• Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma
  di: Hu-Lieskovan, Siwen, et al.
  Pubblicazione: (2015)